Actively Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Led by Ausper Biopharma Co., Ltd. · Updated on 2026-05-04
60
Participants Needed
1
Research Sites
90 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open-label, multicenter phase II clinical study to evaluate the efficacy and safety of AHB-137 injection in participants with CHB previously treated with NA.
CONDITIONS
Official Title
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily participate in the study and sign the informed consent form
- Be between 18 and 65 years old (including boundary ages)
- Have a body mass index that meets study requirements
- Have Chronic Hepatitis B with HBsAg or HBV DNA positive status for at least 6 months
- Meet relevant requirements related to prior medications
- Have HBsAg, HBV DNA, and liver function indicators within required levels
- Use effective contraception as required
You will not qualify if you...
- Have uncontrolled or unstable significant health abnormalities other than Chronic Hepatitis B
- Have other associated liver diseases
- Have any serious infection other than Chronic Hepatitis B that requires intravenous anti-infective therapy
- Test positive for HCV RNA, HIV antibody, or syphilis
- Have abnormal laboratory test results
- Have diseases related to vascular inflammatory conditions
- Have abnormal corrected QT interval by Fridericia method
- Have a history of malignancy or ongoing evaluation for possible malignancy
- Have a history of allergies or allergic constitution
- Have experienced recent major trauma or major surgery, or plan to have surgery
- Are currently participating in another clinical trial or have not completed a required washout period
- Use prohibited medications currently or previously
- Are judged unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
AusperBio Investigational Site
Jilin, Changchun, China
Actively Recruiting
Research Team
L
Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here